New combo therapy targets tough brain tumors

NCT ID NCT03050736

Completed Disease control Sponsor: Kintara Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This phase 2 trial tested a drug called VAL-083 combined with standard radiation in 29 people with newly diagnosed glioblastoma, a fast-growing brain cancer. The study focused on patients whose tumors have a specific genetic marker (unmethylated MGMT) that makes them resistant to standard chemotherapy. The goal was to find the safest dose and see if the combination can shrink tumors or slow their growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VAL-083 (dianhydrogalactitol)
What this could lead to: If successful, this could offer a new treatment option for glioblastoma patients whose tumors do not respond to standard chemotherapy.
What could go wrong: This is a small, early-phase trial with only 29 participants, so results may not apply to all patients. The drug may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer glioblastoma glioma glioma susceptibility 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN CANCER GBM GLIOBLASTOMA GLIOBLASTOMA MULTIFORME GLIOMA

Contacts and locations

Locations

Sun Yat-Sen University Cancer Center

Guangzhou, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.